GlassScriptPhysician profile
Kalpesh G Patel
NPI 1508285065
$9,446.05
in general payments reported to CMS, 2019-2025
36 companies · $2,860 in 2025
The $2,860 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37.58 · 2020: $29.37 · 2021: $294 · 2022: $1,498 · 2023: $1,895 · 2024: $2,831 · 2025: $2,860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,483 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,483.18 |
| Education | $103.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,466.06 | 2020-2025 | |
| Janssen Biotech, INC. | $1,113.49 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Gilead Sciences, INC. | $974.92 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $843.73 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $698.55 | 2021-2025 | Xifaxan, Trulance |
| Boston Scientific Corporation | $477.63 | 2019-2025 | General - Biliary Devices, Exalt Model D |
| Genzyme Corporation | $347.13 | 2023-2025 | |
| Qol Medical, LLC | $344.24 | 2022-2025 | Sucraid, Sucraid |
| Aimmune Therapeutics, INC. | $342.68 | 2024-2025 | Zenpep |
| Madrigal Pharmaceuticals | $305.62 | 2024-2025 | Rezdiffra, Resmetirom |
| Ferring Pharmaceuticals INC. | $291.26 | 2022-2024 | Rebyota, Cimzia |
| Pfizer INC. | $272.21 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $260.45 | 2024 | Reblozyl, Zeposia |
| Lilly USA, LLC | $254.47 | 2023-2025 | Omvoh |
| Ardelyx, INC. | $160.12 | 2022-2025 | Ibsrela |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $131.55 | 2022-2023 | |
| Ethicon US, LLC | $121.84 | 2021 | |
| Ironwood Pharmaceuticals, INC | $111.26 | 2022-2024 | Linzess |
| Regeneron Healthcare Solutions, INC. | $97.71 | 2022-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $92.12 | 2025 | Voquezna |
| Organon LLC | $90.48 | 2023-2024 | Hadlima, Renflexis |
| Merck Sharp & Dohme LLC | $80.68 | 2022-2024 | Dificid |
| Ipsen Biopharmaceuticals, INC | $76.98 | 2024-2025 | Iqirvo |
| Braintree Laboratories, INC. | $74.48 | 2021-2023 | Suflave, Sutab |
| Celltrion USA INC. | $65.09 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Evoke Pharma, INC. | $51.39 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $51.06 | 2024-2025 | |
| Redhill Biopharma INC. | $50.97 | 2022 | |
| Exact Sciences Corporation | $38.55 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Celgene Corporation | $29.26 | 2024 | Zeposia |
| Daiichi Sankyo INC. | $28.77 | 2024 | Injectafer |
| Novo Nordisk INC | $25.26 | 2025 | Wegovy |
| Amgen INC. | $24.34 | 2023 | Avsola |
| Astellas Pharma US INC | $21.58 | 2019 | |
| Intra-Sana Laboratories | $15.86 | 2022 | |
| Tactile Systems Technology INC | $14.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kalpesh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.